The role of BRCA Status on the prognosis of patients with epithelial ovarian cancer: A systematic review of the literature with a meta-analysis

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Sun, Chaoyang ^a   Na, Li ^a   Ding, Dong ^a   Weng, Danhui ^a   Meng, Li ^a   Chen, Gang ^a   Ma, Ding ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; DNA METHYLATION; GENE EXPRESSION; GENE MUTATION; GERM LINE; HUMAN; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SOMATIC MUTATION; SURVIVAL TIME; SYSTEMATIC REVIEW; FEMALE; GENETICS; GERMLINE MUTATION; IMMUNOHISTOCHEMISTRY; META ANALYSIS; METABOLISM; MORTALITY; MUTATION; NEOPLASM; OVARY TUMOR; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PUBLISHING;

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA METHYLATION; FEMALE; GENE EXPRESSION; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; PUBLICATION BIAS;

EID: 84900418322     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095285     Document Type: Article

References (54)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. (2011) Ovarian cancer, five-year stage-specific relative survival rates (2004-2008). J Natl Cancer Inst 103: 1287.
3. Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, et al. (1996) Clinical and pathological features of ovarian cancer in women with germ- line mutations of BRCA1. New England Journal of Medicine 335: 1413-1416. (Pubitemid 26382501)
4. Gallagher DJ, Konner JA, Bell-McGuinn KM, Bhatia J, Sabbatini P, et al. (2011) Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann Oncol 22: 1127-1132.
5. Vencken PM, Kriege M, Hoogwerf D, Beugelink S, van der Burg ME, et al. (2011) Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol 22: 1346-1352.
6. Johannsson OT, Ranstam J, Borg A, Olsson H (1998) Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 16: 397-404. (Pubitemid 28135579)
7. Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, et al. (2008) "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 26: 5530-5536.
8. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, et al. (2011) Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306: 1557-1565.
9. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275: 23899-23903. (Pubitemid 30624678)
10. Davies AA, Masson JY, McIlwraith MJ, Stasiak AZ, Stasiak A, et al. (2001) Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 7: 273-282. (Pubitemid 32206495)
11. Kowalczykowski SC (2002) Molecular mimicry connects BRCA2 to Rad51 and recombinational DNA repair. Nat Struct Biol 9: 897-899.
12. Cooke SL, Brenton JD (2011) Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol 12: 1169-1174.
13. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376: 245-251.
14. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, et al. (2009) Inhibition of poly(ADPribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134.
15. Weberpals JI, Tu D, Squire JA, Amin MS, Islam S, et al. (2011) Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study. Ann Oncol.
16. Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, et al. (2001) Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18: 705-719. (Pubitemid 33040631)
17. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834. (Pubitemid 28562978)
18. Yusuf S, Peto R, Lewis J, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27: 335-371. (Pubitemid 15107153)
19. Sterne JA, Egger M (2001) Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54: 1046-1055. (Pubitemid 32888370)
20. Carser JE, Quinn JE, Michie CO, O'Brien EJ, McCluggage WG, et al. (2011) BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. Gynecol Oncol.
21. Kaern J, Aghmesheh M, Nesland JM, Danielsen HE, Sandstad B, et al. (2005) Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors? International Journal of Gynecological Cancer 15: 1014-1022. (Pubitemid 43110149)
22. Buller RE, Shahin MS, Geisler JP, Zogg M, De Young BR, et al. (2002) Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clinical Cancer Research 8: 1196-1202. (Pubitemid 34520421)
23. Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, et al. (2000) Clinicopatholic features of BRCA-linked and sporadic ovarian cancer. Journal of the American Medical Association 283: 2260-2265. (Pubitemid 30246777)
24. Aida H, Takakuwa K, Nagata H, Tsuneki I, Takano M, et al. (1998) Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. Clinical Cancer Research 4: 235-240. (Pubitemid 28062902)
25. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, et al. (2003) Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97: 2187-2195. (Pubitemid 36444059)
26. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, et al. (2008) Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: The National Israeli Study of Ovarian Cancer. Journal of Clinical Oncology 26: 20-25.
27. Wiley A, Katsaros D, Chen H, Rigault de la Longrais IA, Beeghly A, et al. (2006) Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 107: 299-308. (Pubitemid 44036559)
28. Weberpals J, Garbuio K, O'Brien A, Clark-Knowles K, Doucette S, et al. (2009) The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer 124: 806-815.
29. Zweemer RP, Verheijen RH, Menko FH, Gille JJ, van Diest PJ, et al. (1999) Differences between hereditary and sporadic ovarian cancer. Eur J Obstet Gynecol Reprod Biol 82: 151-153. (Pubitemid 29074311)
30. Chiang JW, Karlan BY, Cass l, Baldwin RL (2006) BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gynecologic Oncology 101: 403-410. (Pubitemid 43729975)
31. Quinn JE, James CR, Stewart GE, Mulligan JM, White P, et al. (2007) BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 13: 7413-7420.
32. Thrall M, Gallion HH, Kryscio R, Kapali M, Armstrong DK, et al. (2006) BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Int J Gynecol Cancer 16 Suppl 1: 166-171.
33. Swisher EM, Gonzalez RM, Taniguchi T, Garcia RL, Walsh T, et al. (2009) Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol Cancer 8: 48.
34. Pharoah PD, Easton DF, Stockton DL, Gayther S, Ponder BA (1999) Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res 59: 868-871.
35. Brozek I, Ochman K, Debniak J, Morzuch L, Ratajska M, et al. (2008) High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland. Gynecologic Oncology 108: 433-437. (Pubitemid 351174286)
36. Zweemer RP, Verheijen RH, Coebergh JW, Jacobs IJ, van Diest PJ, et al. (2001) Survival analysis in familial ovarian cancer, a case control study. European journal of obstetrics, gynecology, and reproductive biology 98: 219-223. (Pubitemid 33713896)
37. Ramus SJ, Fishman A, Pharoah PD, Yarkoni S, Altaras M, et al. (2001) Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations. Eur J Surg Oncol 27: 278-281. (Pubitemid 32621753)
38. Radosa MP, Hafner N, Camara O, Diebolder H, Mothes A, et al. (2011) Loss of BRCA1 Protein Expression as Indicator of the BRCAness Phenotype Is Associated With Favorable Overall Survival After Complete Resection of Sporadic Ovarian Cancer. Int J Gynecol Cancer.
39. Artioli G, Borgato L, Cappetta A, Wabersich J, Mocellin S, et al. (2010) Overall survival in BRCA-associated ovarian cancer: Case-control study of an Italian series. European Journal of Gynaecological Oncology 31: 658-661.
40. Lacour RA, Westin SN, Meyer LA, Wingo SN, Schorge JO, et al. (2011) Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecologic Oncology 121: 358-363.
41. Majdak EJ, Debniak J, Milczek T, Cornelisse CJ, Devilee P, et al. (2005) Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 104: 1004-1012. (Pubitemid 41170228)
42. David YB, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD, et al. (2002) Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. Journal of Clinical Oncology 20: 463-466. (Pubitemid 34072530)
43. Hennessy BTJ, Timms KM, Carey MS, Gutin A, Meyer LA, et al. (2010) Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. Journal of Clinical Oncology 28: 3570-3576.
44. Pal T, Permuth-Wey J, Kapoor R, Cantor A, Sutphen R (2007) Improved survival in BRCA2 carriers with ovarian cancer. Familial Cancer 6: 113-119. (Pubitemid 46295306)
45. Sirisabya N, Manchana T, Termrungreunglert W, Triratanachat S, Charuruks N, et al. (2007) Prevalence of BRCA1 expression in epithelial ovarian cancer: Immunohistochemical study. Journal of the Medical Association of Thailand 90: 9-14.
46. Yu M, Hao J, Jiao Z (2005) A study on the expression of BRCA1 & P53 and their correlation in epithelial ovarian cancer. Chinese Journal of Clinical Oncology 32: 18-20. (Pubitemid 40733073)
47. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, et al. (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutationpositive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30: 2654-2663.
48. Dann RB, DeLoia JA, Timms KM, Zorn KK, Potter J, et al. (2012) BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol 125: 677-682.
49. Gan A, Green AR, Nolan CC, Martin S, Deen S (2013) Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival. Hum Pathol 44: 1638-1647.
50. Hyman DM, Long KC, Tanner EJ, Grisham RN, Arnold AG, et al. (2012) Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. Gynecol Oncol 126: 224-228.
51. McLaughlin JR, Rosen B, Moody J, Pal T, Fan I, et al. (2013) Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst 105: 141-148.
52. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, et al. (2012) Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307: 382-390.
53. Kortmann U, McAlpine JN, Xue H, Guan J, Ha G, et al. (2011) Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res 17: 783-791.
54. Kummar S, Chen A, Ji J, Zhang Y, Reid JM, et al. (2011) Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res 71: 5626-5634.